Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Insmed iPlex Growth Agent “Approvable” Letter Leaves Orphan Status Issue Open

Sep 28 2005

• By Jon Dobson

Related Content

SomatoKine User Fee Goal Date Extended to Oct. 3, Insmed Says

Jun 10 2005

Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity

Aug 31 2005

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window